source
- GSK to acquire cancer drug developer Nuvalent for $10.6 billionGSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…
- Dexcom trial shows continuous glucose monitors improve outcomes across diabetes typesDexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to stan…